Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced a $35.75 million private placement at $3.30 per share to fund its Enhanced Brain Delivery (EBD™) program and general corporate purposes, with closing expected on or about March 16, 2026.
Preclinical EBD data show development candidates achieved 14–40x higher brain exposure in non-human primates, low anemia signal in hematology, stability supporting subcutaneous dosing, and an IND target of mid-2027.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026 at 11:00 a.m. ET. The company is a clinical-stage biopharmaceutical developer targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. The live webcast is available under the Investors tab on the company website and will be archived for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) will present one oral and two poster presentations at the AD/PD conference in Copenhagen, March 17–21, 2026. Presentations cover enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker responses (NULISA-Seq-TM), and novel AβO-targeting antibodies.
The oral talk on March 21 details fusion of sabirnetug with an anti-transferrin receptor fragment; posters on March 17–18 cover biomarker analytics and antibody characterization. The oral data arise from an ongoing collaboration with JCR Pharmaceuticals using J-Brain Cargo® technology and support analytic plans for Phase 2 ALTITUDE‑AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and clinical-trial recruitment data at the 18th Annual CTAD conference on December 1-4, 2025. A collaborative study with JCR Pharmaceuticals showed that fusing transferrin receptor (TfR) binders to AβO-targeting antibodies (including sabirnetug/ACU193) produced 15–68 fold increases in brain penetration in mice while preserving target binding. Acumen and JCR are developing TfR-targeting antibodies for clinical testing. Recruitment analysis from the Phase 2 ALTITUDE-AD trial tracked 2,362 screened across 76 sites with 542 enrolled, finding site databases and physician referrals were the most reliable recruitment methods.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced on Nov 17, 2025 that the first participant was dosed in the open-label extension (OLE) of its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in people with early Alzheimer’s disease.
The OLE offers participants who completed the 18-month placebo-controlled portion additional dosing of 35 mg/kg IV every four weeks for 52 weeks. Clinical measures and safety monitoring remain the same. The company cited Phase 1 INTERCEPT-AD results showing favorable safety, low ARIA-E rates, target engagement, and biomarker effects including amyloid plaque reduction at highest doses. Acumen expects topline ALTITUDE-AD results in late 2026.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q3 2025 results and a business update on Nov. 12, 2025. The company had $136.1 million in cash, cash equivalents and marketable securities as of Sept. 30, 2025, which it expects will support operations into early 2027. Acumen continues its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) and began dosing the open-label extension in Nov. 2025. The company expects non-clinical data for its Enhanced Brain Delivery program in early 2026 and Phase 2 topline results for ALTITUDE-AD in late 2026. Q3 R&D expense was $22.0M and net loss was $26.5M.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced that George Golumbeski, Ph.D. has been appointed Chairman of its Board of Directors, bringing more than 30 years of biopharma experience.
The Board now totals eight members. Management highlighted Golumbeski’s expertise in portfolio strategy, collaborations, licensing and M&A and said his experience aligns with anticipated catalysts next year for Acumen’s Phase 2 sabirnetug trial and its Enhanced Brain Delivery program.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report third quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the live webcast link will be provided and an archived webcast will be available for at least 30 days in the Investors section of the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) said management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025 at 4:40 p.m. ET. The company is a clinical-stage biopharmaceutical developer focused on therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. A live webcast will be available via the company Investors page and archived for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference with a fireside chat on September 2 at 3:15 p.m. ET, and the Cantor Global Healthcare Conference 2025 with a fireside chat on September 5 at 9:10 a.m. ET. Both presentations will be available via webcast on the company's website for 90 days.